It has been found that Slc44a2 is involved in the direct adhesion and activation of neutrophils to vWF and that Slc44a2/HNA-3a plays an important role in the adhesion and activation of venous neutrophils under inflammation and specific shear (188), highlighting the potential of Slc44a2 as an adjuvant therapeutic target for DVT. This evidence concerns the gene VWF and deep vein thrombosis.